GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) major shareholder Opko Health, Inc. sold 75,000 shares of the business’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $33.72, for a total transaction of $2,529,000.00. Following the completion of the transaction, the insider now owns 3,183,403 shares in the company, valued at approximately $107,344,349.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Opko Health, Inc. also recently made the following trade(s):
- On Friday, July 26th, Opko Health, Inc. sold 60,000 shares of GeneDx stock. The shares were sold at an average price of $33.85, for a total transaction of $2,031,000.00.
- On Monday, July 22nd, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The shares were sold at an average price of $32.61, for a total transaction of $1,630,500.00.
- On Friday, July 19th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The shares were sold at an average price of $32.29, for a total transaction of $807,250.00.
- On Wednesday, July 17th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The shares were sold at an average price of $32.93, for a total transaction of $823,250.00.
- On Friday, July 5th, Opko Health, Inc. sold 36,118 shares of GeneDx stock. The shares were sold at an average price of $28.24, for a total transaction of $1,019,972.32.
- On Wednesday, July 3rd, Opko Health, Inc. sold 14,082 shares of GeneDx stock. The shares were sold at an average price of $28.23, for a total transaction of $397,534.86.
- On Monday, July 1st, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The shares were sold at an average price of $26.63, for a total transaction of $1,331,500.00.
GeneDx Stock Up 2.5 %
WGS stock traded up $0.81 during trading on Friday, reaching $33.53. The stock had a trading volume of 499,397 shares, compared to its average volume of 391,348. GeneDx Holdings Corp. has a one year low of $1.16 and a one year high of $35.65. The company has a quick ratio of 2.99, a current ratio of 3.22 and a debt-to-equity ratio of 0.25. The company’s 50 day moving average is $27.31 and its two-hundred day moving average is $15.55. The company has a market capitalization of $875.80 million, a price-to-earnings ratio of -6.47 and a beta of 2.29.
Analyst Ratings Changes
WGS has been the subject of several recent research reports. TD Cowen boosted their target price on shares of GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Jefferies Financial Group initiated coverage on shares of GeneDx in a research report on Monday, June 3rd. They set a “hold” rating and a $21.00 target price for the company. Craig Hallum initiated coverage on shares of GeneDx in a research report on Wednesday, July 10th. They set a “buy” rating and a $43.00 target price for the company. BTIG Research boosted their target price on shares of GeneDx from $19.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, June 26th. Finally, The Goldman Sachs Group boosted their target price on shares of GeneDx from $12.50 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 17th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $30.20.
View Our Latest Stock Report on GeneDx
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oracle Investment Management Inc. boosted its stake in GeneDx by 531.7% in the first quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock valued at $10,286,000 after acquiring an additional 948,253 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of GeneDx by 4.2% during the 1st quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock valued at $6,460,000 after buying an additional 28,678 shares in the last quarter. Gagnon Securities LLC lifted its stake in shares of GeneDx by 59.3% during the 1st quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock valued at $5,079,000 after buying an additional 207,027 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of GeneDx during the 2nd quarter valued at approximately $9,575,000. Finally, Gagnon Advisors LLC lifted its stake in shares of GeneDx by 41.6% during the 1st quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock valued at $1,930,000 after buying an additional 62,059 shares in the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.
GeneDx Company Profile
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
See Also
- Five stocks we like better than GeneDx
- How to Read Stock Charts for Beginners
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Invest in Blue Chip Stocks
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How to invest in marijuana stocks in 7 steps
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.